Danwang Medical Technology

Established in Shanghai in 2019, Danwang Medical Technology operates at the forefront of regenerative medicine, specializing in organoid technology. The company was founded by Li Junqiang, Hua Guoqiang, and Hans Clevers. Danwang Medical focuses on developing and manufacturing organoid models to advance disease diagnosis, support new drug screening, and aid in tumor marker identification. The company provides these high-fidelity organoid models to the biopharmaceutical sector, research institutions, and hospitals, facilitating new drug development and personalized treatment strategies.

The core of Danwang Medical's business is its proprietary organoid technology platform. This platform allows for the creation of three-dimensional cell culture models, or "mini-organs," that closely mimic the characteristics of human organs and tumors. The company has successfully developed culture systems for a wide range of organoids, including those for the lung, pancreas, breast, stomach, intestine, and liver. Its services encompass providing these organoid models for scientific research, drug screening, toxicology evaluation, and immune co-culture evaluations. A key application is in oncology, where patient-derived tumor organoids are used for drug sensitivity testing, helping to guide personalized cancer treatment within a rapid timeframe, typically around two weeks.

The company's business model is centered on providing both products and services. It offers an extensive organoid biobank, featuring models from various tumor and normal tissues, as well as specific genetic mutation libraries like KRAS and HER2. For its biopharma clients, Danwang provides a comprehensive R&D service platform to validate drug candidates. Additionally, it develops and supplies IVD reagents and automated equipment to help clients efficiently conduct organoid-related research. Financially, Danwang Medical is a venture capital-backed entity, having secured multiple rounds of funding. Its initial seed round in February 2021 involved investors such as Co-win Ventures, Delian Capital, and Kunlun Capital. Subsequent funding rounds, including a Series A in October 2021 and a later-stage VC round in December 2024, have supported its growth and revenue generation.

Keywords: organoid technology, regenerative medicine, biopharmaceutical services, personalized medicine, drug screening, cancer research, organoid models, disease diagnosis, tumor organoids, 3D cell culture, preclinical research, drug development, oncology, toxicology testing, biobank, CRO services, precision oncology, IVD reagents, automated lab equipment, clinical research